Sarah Gheuens Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

Sarah Gheuens is Chief Medical Officer of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 61,271 shares of AGIO, which is worth approximately $2.39 Million. The most recent transaction as insider was on Jul 09, 2025, when has been sold 11,914 shares (Common Stock) at a price of $38.34 per share, resulting in proceeds of $456,782. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 61.3K

13.68% 3M change

40.09% 12M change

Total Value Held $2.39 Million

Sarah Gheuens Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 09 2025	SELL Open market or private sale	$456,782 $38.34 p/Share	11,914 Reduced 16.28%	61,271 Common Stock
Jul 09 2025	BUY Exercise of conversion of derivative security	$297,969 $25.01 p/Share	11,914 Added 14.0%	73,185 Common Stock
Jul 01 2025	SELL Open market or private sale	$139,789 $34.17 p/Share	4,091 Reduced 6.26%	61,271 Common Stock
Jul 01 2025	BUY Exercise of conversion of derivative security	-	8,374 Added 11.36%	65,362 Common Stock
Jun 24 2025	SELL Open market or private sale	$97,567 $33.54 p/Share	2,909 Reduced 4.86%	56,988 Common Stock
Jun 24 2025	BUY Exercise of conversion of derivative security	-	6,000 Added 9.11%	59,897 Common Stock
Mar 03 2025	SELL Open market or private sale	$142,337 $35.54 p/Share	4,005 Reduced 6.92%	53,897 Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	13,500 Added 19.54%	55,578 Common Stock
Jul 01 2024	SELL Open market or private sale	$162,464 $43.85 p/Share	3,705 Reduced 7.81%	43,736 Common Stock
Jul 01 2024	BUY Exercise of conversion of derivative security	-	8,375 Added 15.0%	47,441 Common Stock
Mar 05 2024	SELL Open market or private sale	$86,049 $32.57 p/Share	2,642 Reduced 6.33%	39,066 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	7,834 Added 16.24%	40,415 Common Stock
Feb 14 2024	SELL Open market or private sale	$16,139 $25.14 p/Share	642 Reduced 1.88%	33,431 Common Stock
Feb 12 2024	BUY Exercise of conversion of derivative security	-	2,162 Added 5.97%	34,073 Common Stock
Jan 24 2024	SELL Open market or private sale	$36,961 $21.64 p/Share	1,708 Reduced 5.08%	31,911 Common Stock
Jan 20 2024	BUY Exercise of conversion of derivative security	-	5,750 Added 14.61%	33,619 Common Stock
Jan 09 2024	SELL Open market or private sale	$41,129 $22.99 p/Share	1,789 Reduced 6.03%	27,869 Common Stock
Jan 05 2024	BUY Exercise of conversion of derivative security	-	5,000 Added 14.43%	29,658 Common Stock
Jun 30 2023	SELL Open market or private sale	$48,410 $28.36 p/Share	1,707 Reduced 6.6%	24,159 Common Stock
Jun 28 2023	BUY Exercise of conversion of derivative security	-	5,750 Added 18.19%	25,866 Common Stock
Mar 03 2023	SELL Payment of exercise price or tax liability	$28,372 $25.02 p/Share	1,134 Reduced 5.34%	20,116 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	-	3,833 Added 15.28%	21,250 Common Stock
Feb 14 2023	SELL Payment of exercise price or tax liability	$21,557 $28.44 p/Share	758 Reduced 4.27%	17,009 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	2,162 Added 10.85%	17,767 Common Stock
Dec 28 2022	SELL Payment of exercise price or tax liability	$79,259 $28.48 p/Share	2,783 Reduced 15.13%	15,605 Common Stock

Also insider at

VRDN

Viridian Therapeutics, Inc.\DE Healthcare

Sarah Gheuens

Chief Medical Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Value

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

Operation

Value

Type

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Track Activities on AGIO

Account